Table 3 Changes in baseline BP measurements for non-responders at the end of therapy
Efficacy Parameters | Metoprolol XL + Chlorthalidone (n = 30) | Metoprolol XL + HCTZ (n = 30) | P value |
|---|---|---|---|
Mean SBP (mmHg) (At 4 weeks) | 139.23 ± 10.40 (120.0-160.0) | 141.40 ± 13.29 (116.0-172.0) | 0.485 |
Mean SBP (mmHg) (At 12 weeks) | 127.40 ± 12.54 (106.0-134.0) | 133.57 ± 13.76 (100.0-164.0) | 0.075 |
Mean DBP (mmHg) (At 4 weeks) | 87.57 ± 7.94 (70.0-96.0) | 89.57 ± 6.37 (80.0-98.0) | 0.287 |
Mean DBP (mmHg) (At 12 weeks) | 81.80 ± 7.61 (70.0-88.0) | 85.43 ± 8.01 (70.0-104.0) | 0.077 |
Mean Fall in SBP (mmHg) | -11.8 ± 13.8 | -7.8 ± 14.4 | 0.277 |
Mean Fall in DBP (mmHg) | -5.8 ± 10.7 | -4.13 ± 7.98 | 0.507 |
Responders | 25 | 19 | 0.045 |
Non-responders | 5 | 11 | Â |